Cord blood stem cells

One Million Blood Stem Cell Transplants Worldwide and background to the first Umbilical Cord Blood Transplant

Use of Cord Blood Stem Cells – A Medical Resource
Hematopoietic stem cells (HSCs) – This blood contains powerful stem cells that have been used to regenerate healthy blood and immune which create blood and immune cells . More than 30,000 cord blood stem cell transplants performed worldwide to date –  Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond. Blood. 2013.

Diseases Treated with Stem Cells – Cancers, Blood, Immune & Metabolic Disorders
Used to treat more than 80 diseases, including various cancers and blood, immune, and metabolic disorders – Brunstein CG, Setubal DC, Wagner JE. Expanding the role of umbilical cord blood transplantation. Br J Haematol. 2007; 137(1):20-35.

Regenerative medicine
Clinical trials are currently evaluating the use of cord blood stem cells as a potential treatment for conditions like cerebral palsy, traumatic brain injury, and paediatric stroke. Laboratory research suggests promise across a variety of therapeutic areas including Alzheimer’s disease, lung injury, heart disease, and spinal cord injury –

Why red blood cells should be removed before cord blood storage
Very early in the field of cord blood banking, laboratories that process cord blood for storage began removing most of the plasma (plasma depletion) and the red blood cells (RBC depletion) before cryopreserving the remaining component of the blood that holds the stem cells.
Parent’s Guide to Cord Blood November Newsletter 2014


The Joint Accreditation Committee-ISCT & EBMT (JACIE) which issues standards to promote high quality laboratory performance in haematopoietic stem cell collection, processing and transplantation state the following with regard to cord blood at the time of transplant:

B7.6.2 There shall be a policy for volume of ABO-incompatible red cells in allogeneic cellular
therapy products.
B7.6.3 There shall be consultation with the Processing Facility regarding cord blood preparation for administration.
B7.6.3.1 Cord blood units that have not been red cell reduced prior to cryopreservation shall be washed prior to administration.
For cord blood units, the NMDP recommends the washing procedure in Appendix F of the 0501 protocol, available at, and requires washing of red cell replete CB units due to unexpected adverse events.

Source: FACT-JACIE International Standards for Hematopoietic Cellular Therapy
Product Collection, Processing, and Administration, Sixth Edition

Cord tissue stem cells

Reviews of the primary literature and primary literature publications discussing pre-clinical research and the potential use of cord tissue in regenerative medicine.

1          Review: Therapeutic-Potentials-of-Mesenchymal-Stem-Cells-Derived-from-Human-Umbilical-Cord: Stem Cell Rev and Rep DOI 10.1007/s12015-010-9168-8

Fat cells, bone cells, cartilage cells, skeletal muscle cells, cardiac cells, endothelial cells, hepatocyte-like cells, islet-like cells, neurons, astrocytes and oligodentrocytes in vitro and in vivo.

2          Review:  Human UC Mesenchymal Stem Cells: A New Era for Stem Cell Therapy: Cell Transplantation,. 24, pp. 339–347, 2015

Cerebral ischemia , Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, retinal disease, Type 1 and type 2 diabetes, myogenic disease.

3          Differentiation of Human Umbilical Cord Matrix Mesenchymal Stem Cells into Neural-Like Progenitor Cells and Maturation into an Oligodendroglial-Like Lineage: 1 October 2014, Vol 9, Issue 10, e111059

Neuronal differentiation and potential for future therapeutic use.

4          Re-endothelialisation of Human Heart Valve Neo scaffolds using Umbilical Cord-Derived Endothelial Cells: Circulation Journal, 77, 207-216, 2013

Cardiac vascular repair and potential for future therapeutic use.

5          Improving Viability and Transfection Efficiency with Human Umbilical Cord Wharton’s Jelly Cells through use of a ROCK Inhibitor: Cellular reprogramming, 16, 2, 91-97, 2014

General stem cell therapy and gene therapy for regenerative medicine applications: Endocrine Journal, 60, 3, 347-357, 2013

Trials using cord tissue currently in the registry and results database and WHO International Trials Registry Platform
A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients with RRMS
Clinical Study of Umbilical Cord Tissue Mesenchymal Stem Cells (UC-MSC) for Treatment of Osteoarthritis
Safety and Feasibility Study of Cell Therapy in Treatment of Spinal Cord Injury
Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis
Umbilical Cord Tissue-derived Mesenchymal Stem Cells for Rheumatoid Arthritis
Safety and Exploratory Efficacy Study of UCMSCs in Patients With Ischemic Heart Disease (SEESUPIHD)
Umbilical Cord Mesenchymal Stem Cells Transplantation to Patients With Spinal Cord Injury
Mesenchymal Stem Cells to Treat Type II Diabetes (UC-MSCs)
Human Umbilical Cord Mesenchymal Stem Cell Transplantation in Articular Cartilage Defect


Wharton’s Jelly : potential in regenerative medicine

1          New Frontiers in Regenerative Medicine in Cardiology: The Potential of Wharton’s Jelly Mesenchymal Stem Cells: Current Stem Cell Research & Therapy, , 8, 39-45, 2013

Potential for cardiac therapeutics

2          Mesenchymal Stem Cells in the Wharton’s Jelly of the Human Umbilical Cord: Stem Cells; 22:1330–1337, 2004

Multi-lineage potential of MSCs from Wharton’s jelly

3          Mesenchymal Stem Cells Derived from Wharton’s Jelly of the Umbilical Cord: Biological Properties and Emerging Clinical Applications: Current Stem Cell Research & Therapy, 2013, 8, 144-155

Potential application for the treatment of cancer and immune mediated disorders, graft versus host disease  and systemic lupus erythematosus and possible application in supporting haematopoietic stem cell expansion.

4          Wharton’s Jelly-Derived Mesenchymal Stem Cells: Phenotypic Characterization and Optimizing their Therapeutic Potential for Clinical Applications: Int. J. Mol. Sci. 2013, 14, 11692-11712; doi:10.3390/ijms140611692

Potential advantages as transplantable cells for treatment of various diseases (e.g., cancer, chronic liver disease, cardiovascular diseases, nerve, cartilage and tendon injury). Further studies required to translate research into the clinical setting.

5          Long term effects of the implantation of Wharton’s jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus: Endocr J. 60(3):347-57, 2013;

Diabetes – research and potential for future therapeutic use.

Clinical trials by indication

Cerebral Palsy
Mesenchymal stem cells are taken from the umbilical cord and are extremely useful as they are not immediately recognized as foreign by the body. The cells secrete molecules called trophic factors and these molecules are known to encourage repair of damaged tissue in both the brain and spinal cord.
Stem Cell Treatments for Cerebral Palsy  –  Mary Washington’s Story  –

Clinical Trial – Safety and Effectiveness of Cord Blood Stem Cell Infusion for the Treatment of Cerebral Palsy in Children
The purpose of this study is to test the safety and effectiveness of a cord blood infusion in children who have motor disability due to cerebral palsy (CP). The subjects will be children whose parents have saved their infant’s cord blood, who have non-progressive motor disability, and whose parents intend to have a cord blood infusion.
Responsible Party: James E. Carroll, Professor and Chief, Child Neurology, Georgia Regents University
Georgia Regents University   (NCT01072370)

Bone Formation
Over 60,000 hip, 50,000 wrist and 120,000 vertebral fractures occur each year in the UK. Fractures in bones usually take around 3-6 months to go back to normality. The inability to repair normally occurs in 1% of all fractures.

Treatment of Non Union of Long Bone Fractures by Autologous Mesenchymal Stem Cell
The definition of nonunion is a failure of the fracture to heal within six months in a patient it is a serious complication, occurring in 2-10% of patients. The purpose of this study is to find if mesenchymal stem cells can stimulate bone regeneration in nonunion and delayed union fractures to reduce later surgeries required to augment the healing process and to accelerate the time to healing.
Royal Institute   (NCT01206179)

Allogeneic Stem Cell Transplantation in Systemic Lupus Erythematosus

Sickle Cell
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia

Perspectives on the Use of Stem Cells for Autism Treatment
Dario Siniscalco,1,2,3 James Jeffrey Bradstreet,4 Nataliia Sych,5 and Nicola Antonucci6
1Department of Experimental Medicine, Second University of Naples, Via S. Maria di Costantinopoli, 16-80138 Napoli, Italy
2Centre for Autism, La Forza del Silenzio, 81036 Caserta, Italy
3Cancellautismo, 50132 Florence, Italy
4International Child Development Resource Center, Chateau Élan, Braselton, GA 30517, USA
5Clinical Department, Cell Therapy Center EmCell, Kiev 04073, Ukraine
6Biomedical Centre for Autism Research and Treatment, 70126 Bari, Italy
Received 10 May 2013; Revised 22 August 2013; Accepted 6 September 2013
Academic Editor: Chen Lin
Copyright © 2013 Dario Siniscalco et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Safety and Efficacy of Stem Cell Therapy in Patients with Autism

Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism

Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy for Autism
Allogeneic (not from the subject) human umbilical cord tissue-derived stem cells administered intravenously (IV) in a series of 4 infusions every 3 months over the course of one year is safe and will induce a therapeutic effect in autism patients.

Type 1 Diabetes

Type 2 Diabetes

Umbilical cord mesenchymal stem cell transplantation for treatment of type2 diabetes
A preliminary evaluation of efficacy and safety of Wharton’s jelly mesenchymal stem cell transplantation in patients with type 2 diabetes mellitus

Efficacy of Umbilical cord Mesenchymal stem cells transplantation in the treatment of brainstem disease patients

Efficacy of umbilical cord mesenchymal stem cell transplantation in the treatment of cirrhosis patients

Efficacy of Umbilical cord Mesenchymal stem cells transplantation in the treatment of brain trauma sequela patients

The safety and efficacy of umbilical cord mesenchymal stem cell transplantation through femoral artery interventional procedure in spinal cord injury patients

Comparative analysis on the curative effect between umbilical cord mesenchymal stem cell transplantation and anti-diabetic treatment

Safety and efficacy study of Umbilical cord mesenchymal stem cells transplantation for treatment of Parkinson’s disease

Comparing of effect of umbilical cord mesenchymal stem cell therapy on motor function of twin cerebral palsy

Umbilical cord blood (umbilical cord mesenchymal ) stem cell in patients with end stage liver diseases

Start typing and press Enter to search